Daratumumab and Isatuximab Differentially Affect CD38 Detection on Plasma Cells in Myeloma: Anti-CD38 Nanobody (clone JK36) and CD319 Combination Improve Flow Cytometric Identification of Plasma Cells after Targeted Therapies.
British journal of haematology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined